A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Pathologically confirmed diagnosis of advanced NSCLC
Whose physician has already decided to initiate a treatment with nivolumab for the treatment of advanced NSCLC according to the European label
Previously treated with at least one prior chemotherapy- containing regimen
You may not be if
Participants taking part in an interventional study for lung cancer treatment for which nivolumab is one of the investigational drugs
Participants with a diagnosis of another primary cancer within the past five years
Participants receiving IO within 12 weeks prior to nivolumab first infusion in the context of the present study
Clareo Health | A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy
